| Basics |
Codexis, Inc.
Codexis Inc is a biotech company. It develops proprietary biocatalysts-enzymes or microbes that initiate or accelerate chemical reactions. It offers its products to the pharmaceutical industry. The company also develops advanced biofuels.
|
| IPO Date: |
April 22, 2010 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$165.29M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.22 | 2.80%
|
| Avg Daily Range (30 D): |
$0.06 | 3.30%
|
| Avg Daily Range (90 D): |
$0.07 | 2.86%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.34M |
| Avg Daily Volume (30 D): |
1.12M |
| Avg Daily Volume (90 D): |
.89M |
| Trade Size |
| Avg Trade Size (Sh.): |
112 |
| Avg Trade Size (Sh.) (30 D): |
190 |
| Avg Trade Size (Sh.) (90 D): |
162 |
| Institutional Trades |
| Total Inst.Trades: |
1,257 |
| Avg Inst. Trade: |
$1.46M |
| Avg Inst. Trade (30 D): |
$1.06M |
| Avg Inst. Trade (90 D): |
$1.23M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.28M |
| Avg Closing Trade (30 D): |
$.72M |
| Avg Closing Trade (90 D): |
$.77M |
| Avg Closing Volume: |
92.46K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-.22
|
|
|
Diluted EPS
|
|
$-.22
|
|
|
Revenue
|
$
|
$ 8.6M
|
$
|
|
Gross Profit
|
$
|
$ 6.14M
|
$
|
|
Net Income / Loss
|
$
|
$ -19.62M
|
$
|
|
Operating Income / Loss
|
$
|
$ -18.95M
|
$
|
|
Cost of Revenue
|
$
|
$ 2.47M
|
$
|
|
Net Cash Flow
|
$
|
$
|
$
|
|
PE Ratio
|
|
|
|
|
|
|
